TY - JOUR

T1 - Oncolytic viruses as promising agents for treating glioblastoma

AU - Венглер, Денис Сергеевич

AU - Кулигина, Елена Владимировна

AU - Васильева, Наталья Сергеевна

AU - Рихтер, Владимир Александрович

AU - Чернышова, Алёна Леонидовна

AU - Тамкович, Светлана Николаевна

N1 - Oncolytic viruses as promising agents for treating glioblastoma / D. E. Vengler, E. V. Kuligina, N. S. Vasileva [et al.] // Siberian Journal of Oncology. – 2025. – Vol. 24, No. 6. – P. 138-148. – DOI 10.21294/1814-4861-2025-24-6-138-148. – EDN FPQAUS. The study was supported by the grant No. 24-14-00390 from the Russian Science Foundation (https://rscf. ru/en/project/24-14-00390/).

PY - 2025

Y1 - 2025

N2 - Background. Glioblastoma is a highly aggressive, difficult-to-treat brain cancer with a poor prognosis, high mortality, and a significant impact on quality of life. Despite decades of research, standard treatments can extend life, but do not cure the disease, making it a focus for new research in neuro-oncology, immunotherapy, targeted therapy, and personalized medicine. The disease affects people of working age (with peak incidence between 45 and 70 years of age), causing damage to families and society. High costs of treatment and palliative care exacerbate the problem. The purpose of the study was to summarize data on modern approaches to the treatment of glioblastoma and to analyze efficacy and side effects of oncolytic virus therapy. Material and Methods. The literature review of studies published over the past 10 years was conducted using PubMed, eLIBRARY, Springer, Google Scholar, etc. databases.Results. Modern glioma therapy uses a multidisciplinary approach combining surgery, chemotherapy, and radiation therapy. Oncolytic virotherapy for brain glioma is a promising field because it uses viruses to selectively target to cancer cells while also stimulating an immune response against the tumor. Current research confirms that oncolytic therapy is effective against a variety of tumors including those that are resistant to traditional treatments. Clinical studies show that virotherapy can be a safe treatment because viruses are often engineered to be selective for cancer cells like glioma, minimizing damage to healthy tissue, although questions remain about optimizing dosage and overcoming the immune response.Conclusion. Oncolytic virotherapy is a highly promising approach for the treatment of glioblastoma. Oncolytic viruses are currently in various stages of research, and have promise in animal models, with the potential to lead to new personalized treatments for solid tumors.

AB - Background. Glioblastoma is a highly aggressive, difficult-to-treat brain cancer with a poor prognosis, high mortality, and a significant impact on quality of life. Despite decades of research, standard treatments can extend life, but do not cure the disease, making it a focus for new research in neuro-oncology, immunotherapy, targeted therapy, and personalized medicine. The disease affects people of working age (with peak incidence between 45 and 70 years of age), causing damage to families and society. High costs of treatment and palliative care exacerbate the problem. The purpose of the study was to summarize data on modern approaches to the treatment of glioblastoma and to analyze efficacy and side effects of oncolytic virus therapy. Material and Methods. The literature review of studies published over the past 10 years was conducted using PubMed, eLIBRARY, Springer, Google Scholar, etc. databases.Results. Modern glioma therapy uses a multidisciplinary approach combining surgery, chemotherapy, and radiation therapy. Oncolytic virotherapy for brain glioma is a promising field because it uses viruses to selectively target to cancer cells while also stimulating an immune response against the tumor. Current research confirms that oncolytic therapy is effective against a variety of tumors including those that are resistant to traditional treatments. Clinical studies show that virotherapy can be a safe treatment because viruses are often engineered to be selective for cancer cells like glioma, minimizing damage to healthy tissue, although questions remain about optimizing dosage and overcoming the immune response.Conclusion. Oncolytic virotherapy is a highly promising approach for the treatment of glioblastoma. Oncolytic viruses are currently in various stages of research, and have promise in animal models, with the potential to lead to new personalized treatments for solid tumors.

KW - GLIOBLASTOMA

KW - VIROTHERAPY

KW - ONCOLYTIC VIRUS FOR THE TREATMENT OF GLIOBLASTOMA

KW - VACCINIA VIRUS

KW - RECURRENT GLIOBLASTOMA

KW - MODERN APPROACHES TO THE TREATMENT OF GLIOBLASTOMA

UR - https://www.elibrary.ru/item.asp?id=88828184

U2 - 10.21294/1814-4861-2025-24-6-138-148

DO - 10.21294/1814-4861-2025-24-6-138-148

M3 - Article

VL - 24

SP - 138

EP - 148

JO - Siberian Journal of Oncology

JF - Siberian Journal of Oncology

SN - 1814-4861

IS - 6

ER -